AIDS and Behavior

, Volume 20, Issue 12, pp 2950–2960 | Cite as

Attitudes Toward Addiction, Methadone Treatment, and Recovery Among HIV-Infected Ukrainian Prisoners Who Inject Drugs: Incarceration Effects and Exploration of Mediators

  • Maxim Polonsky
  • Julia Rozanova
  • Lyuba Azbel
  • Chethan Bachireddy
  • Jacob Izenberg
  • Tetiana Kiriazova
  • Sergii Dvoryak
  • Frederick L. Altice
Original Paper

Abstract

In this study, we use data from a survey conducted in Ukraine among 196 HIV-infected people who inject drugs, to explore attitudes toward drug addiction and methadone maintenance therapy (MMT), and intentions to change drug use during incarceration and after release from prison. Two groups were recruited: Group 1 (n = 99) was currently incarcerated and Group 2 (n = 97) had been recently released from prison. This paper’s key finding is that MMT treatment and addiction recovery were predominantly viewed as mutually exclusive processes. Group comparisons showed that participants in Group 1 (pre-release) exhibited higher optimism about changing their drug use, were less likely to endorse methadone, and reported higher intention to recover from their addiction. Group 2 participants (post-release), however, reported higher rates of HIV stigma. Structural equation modeling revealed that in both groups, optimism about recovery and awareness of addiction mediated the effect of drug addiction severity on intentions to recover from their addiction.

Keywords

Methadone HIV Prisoners Opioid Agonist Therapies Addiction Ukraine Structural Equation Modeling 

Notes

Acknowledgments

This research received funding from the National Institute on Drug Abuse for research (R01 DA029910 and R01 DA033679) and career development (K24 DA017072), the Yale University School of Medicine’s Office of Student Research, the Yale University Global Health Initiative, the International Renaissance Foundation, and the NIH Fogarty Research Training Grant (R25 TW009338). No funding source had any role in study design, collection or analysis of data, writing or review of the manuscript, or decision to submit this paper for publication.

References

  1. 1.
    WHO. HIV/AIDS surveillance in Europe 2013 Geneva, Switzerland: European Center for Disease Control; 2013. http://www.euro.who.int/__data/assets/pdf_file/0007/264931/HIV-AIDS-surveillance-in-Europe-2013-Eng.pdf?ua=1. Accessed 2 Aug 2 2015
  2. 2.
    UNAIDS. Ukraine country progress report. Geneva, Switzerland United Nations AIDS Program; 2014. http://www.unaids.org/en/regionscountries/countries/ukraine. Accessed 2 Aug 2015
  3. 3.
    UNAIDS. Religious leaders and faith-based organizations reinforce their role in the AIDS response amid Ukraine’s humanitarian crisis. Geneva, Switzerland 2015 United Nations AIDS Program; 2015. http://www.unaids.org/en/resources/presscentre/featurestories//february/20150212_ukraine. Accessed 2 Aug 2015
  4. 4.
    MoHo Ukraine. Ukraine harmonised AIDS response progress report. Kyiv: Ministry of Health of Ukraine; 2012.Google Scholar
  5. 5.
    Čakalo JI, Božičević I, Vitek C, Mandel JS, Salyuk T, Rutherford GW. Misclassification of men with reported HIV infection in Ukraine. AIDS Behav. 2015;19(10):1938–40.CrossRefPubMedGoogle Scholar
  6. 6.
    Petersen Z, Myers B, van Hout MC, Pluddemann A, Parry C. Availability of HIV prevention and treatment services for people who inject drugs: findings from 21 countries. Harm Reduct J. 2013;10:13.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Bobrovskyy O, Eschenko O, Havovych Y, Kobyschcha Y. Ukraine harmonized AIDS response progress report. Kyiv: International HIV/AIDS Alliance; 2012.Google Scholar
  8. 8.
    WHO. HIV in prisons. Geneva, Switzerland: World Health Organization 2015. http://www.euro.who.int/en/health-topics/communicable-diseases/hivaids/policy/policy-guidance-for-key-populations-most-at-risk2/hiv-in-prisons. Accessed 2 Aug 2015
  9. 9.
    Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Burden of infectious diseases, substance use disorders, and mental illness among Ukrainian prisoners transitioning to the community. PLoS One. 2013;8(3):e59643.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Azbel L, Wickersham JA, Grishaev Y, Dvoryak S, Altice FL. Correlates of HIV infection and being unaware of HIV status among soon-to-be-released Ukrainian prisoners. J Int AIDS Soc. 2014;17(1):19005.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Azbel L, Wickersham JA, Wegman MP, Polonsky M, Suleymanov M, Ismayilov R, et al. Burden of substance use disorders, mental illness, and correlates of infectious diseases among soon-to-be released prisoners in Azerbaijan. Drug Alcohol Depend. 2015;151:68–75.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Amato L, Davoli M, Perucci CA, Ferri M, Faggiano F, Mattick RP. An overview of systematic reviews of the effectiveness of opiate maintenance therapies: available evidence to inform clinical practice and research. J Subst Abuse Treat. 2005;28(4):321–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Mattick RP, Kimber J, Breen C, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2008;2008(2):CD002207.Google Scholar
  14. 14.
    Alistar SS, Owens DK, Brandeau ML. Effectiveness and cost effectiveness of expanding harm reduction and antiretroviral therapy in a mixed HIV epidemic: a modeling analysis for Ukraine. PLoS Med. 2011;8(3):e1000423.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Kim SW, Pulkki-Brannstrom AM, Skordis-Worrall J. Comparing the cost effectiveness of harm reduction strategies: a case study of the Ukraine. Cost Eff Resour Alloc C/E. 2014;12:25.CrossRefPubMedGoogle Scholar
  16. 16.
    Hedrich D, Alves P, Farrell M, Stover H, Moller L, Mayet S. The effectiveness of opioid maintenance treatment in prison settings: a systematic review. Addiction. 2012;107(3):501–17.CrossRefPubMedGoogle Scholar
  17. 17.
    Kinlock TW, Gordon MS, Schwartz RP, Fitzgerald TT, O’Grady KE. A randomized clinical trial of methadone maintenance for prisoners: results at 12 months postrelease. J Subst Abuse Treat. 2009;37(3):277–85.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, et al. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350–9.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    MacArthur GJ, Minozzi S, Martin N, Vickerman P, Deren S, Bruneau J, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    MacArthur GJ, van Velzen E, Palmateer N, Kimber J, Pharris A, Hope V, et al. Interventions to prevent HIV and Hepatitis C in people who inject drugs: a review of reviews to assess evidence of effectiveness. Int J Drug Policy. 2014;25(1):34–52.CrossRefPubMedGoogle Scholar
  21. 21.
    Altice FL, Kamarulzaman A, Soriano VV, Schechter M, Friedland GH. Treatment of medical, psychiatric, and substance-use comorbidities in people infected with HIV who use drugs. Lancet. 2010;376(9738):367–87.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Sarang A, Stuikyte R, Bykov R. Implementation of harm reduction in Central and Eastern Europe and Central Asia. Int J Drug Policy. 2007;18(2):129–35.CrossRefPubMedGoogle Scholar
  23. 23.
    Torrens M, Fonseca F, Castillo C, Domingo-Salvany A. Methadone maintenance treatment in Spain: the success of a harm reduction approach. Bull World Health Organ. 2013;91(2):136–41.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Zaller N, Mazhnaya A, Larney S, Islam Z, Shost A, Prokhorova T, et al. Geographic variability in HIV and injection drug use in Ukraine: Implications for integration and expansion of drug treatment and HIV care. Int J Drug Policy. 2015;26(1):37–42.CrossRefPubMedGoogle Scholar
  25. 25.
    Degenhardt L, Mathers BM, Wirtz AL, Wolfe D, Kamarulzaman A, Carrieri MP, et al. What has been achieved in HIV prevention, treatment and care for people who inject drugs, 2010–2012? A review of the six highest burden countries. Int J Drug Policy. 2014;25(1):53–60.CrossRefPubMedGoogle Scholar
  26. 26.
    Polonsky M, Azbel L, Wickersham JA, Taxman FS, Grishaev E, Dvoryak S, et al. Challenges to implementing opioid substitution therapy in Ukrainian prisons: personnel attitudes toward addiction, treatment, and people with HIV/AIDS. Drug Alcohol Depend. 2015;148:47–55.CrossRefPubMedGoogle Scholar
  27. 27.
    Jurgens R, Ball A, Verster A. Interventions to reduce HIV transmission related to injecting drug use in prison. Lancet Infect Dis. 2009;9(1):57–66.CrossRefPubMedGoogle Scholar
  28. 28.
    Jurgens R, Nowak M, Day M. HIV and incarceration: prisons and detention. J Int AIDS Soc. 2011;14:26.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Oser CB, Knudsen HK, Staton-Tindall M, Taxman F, Leukefeld C. Organizational-level correlates of the provision of detoxification services and medication-based treatments for substance abuse in correctional institutions. Drug Alcohol Depend. 2009;103(Suppl 1):S73–81.CrossRefPubMedGoogle Scholar
  30. 30.
    Taxman FS, Cropsey KL, Melnick G, Perdoni ML. COD services in community correctional settings: an examination of organizational factors that affect service delivery. Behav Sci Law. 2008;26(4):435–55.CrossRefPubMedGoogle Scholar
  31. 31.
    Taxman FS, Henderson CE, Belenko S. Organizational context, systems change, and adopting treatment delivery systems in the criminal justice system. Drug Alcohol Depend. 2009;103:S1–6.CrossRefPubMedGoogle Scholar
  32. 32.
    Springer SA, Bruce RD. A pilot survey of attitudes and knowledge about opioid substitution therapy for HIV-infected prisoners. J Opioid Manag. 2008;4(2):81–6.PubMedPubMedCentralGoogle Scholar
  33. 33.
    McKenzie M, Nunn A, Zaller ND, Bazazi AR, Rich JD. Overcoming obstacles to implementing methadone maintenance therapy for prisoners: implications for policy and practice. J Opioid Manag. 2009;5(4):219–27.PubMedPubMedCentralGoogle Scholar
  34. 34.
    Bruce RD, Dvoryak S, Sylla L, Altice FL. HIV treatment access and scale-up for delivery of opiate substitution therapy with buprenorphine for IDUs in Ukraine–programme description and policy implications. Int J Drug Policy. 2007;18(4):326–8.CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Kraus SJ. Attitudes and the prediction of behavior: a meta-analysis of the empirical literature. Pers Soc Psychol Bull. 1995;21(1):58–75.CrossRefGoogle Scholar
  36. 36.
    Pomery EA, Gibbons FX, Reis-Bergan M, Gerrard M. From willingness to intention: experience moderates the shift from reactive to reasoned behavior. Pers Soc Psychol Bull. 2009;35(7):894–908.CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Schwartz RP, Kelly SM, O’Grady KE, Mitchell SG, Brown BS. Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts. Drug Alcohol Depend. 2011;115(1–2):23–9.CrossRefPubMedGoogle Scholar
  38. 38.
    Morozova O, Azbel L, Grishaev Y, Dvoryak S, Wickersham JA, Altice FL. Ukrainian prisoners and community reentry challenges: implications for transitional care. Int J Prison Health. 2013;9(1):5–19.CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Choi P, Kavasery R, Desai MM, Govindasamy S, Kamarulzaman A, Altice FL. Prevalence and correlates of community re-entry challenges faced by HIV-infected male prisoners in Malaysia. Int J STD AIDS. 2010;21(6):416–23.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Izenberg JM, Bachireddy C, Wickersham JA, Soule M, Kiriazova T, Dvoriak S, et al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour. Int J Drug Policy. 2014;25(5):845–52.CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013;133(1):154–60.CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Bullinger M, Alonso J, Apolone G, Leplege A, Sullivan M, Wood-Dauphinee S, et al. Translating health status questionnaires and evaluating their quality: the IQOLA Project approach. International Quality of Life Assessment. J Clin Epidemiol. 1998;51(11):913–23.CrossRefPubMedGoogle Scholar
  43. 43.
    Brislin RW. Back-translation for cross-cultural research. J Cross Cult Psych. 1970;1:185–216.CrossRefGoogle Scholar
  44. 44.
    Wickersham JA, Azar MM, Cannon CM, Altice FL, Springer SA. Validation of a brief measure of opioid dependence: the rapid opioid dependence screen (RODS). J Correct Health Care. 2015;21(1):12–26.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Nilssen O, Averina M, Brenn T, Brox J, Kalinin A, Archipovski V. Alcohol consumption and its relation to risk factors for cardiovascular disease in the north-west of Russia: the Arkhangelsk study. Int J Epidemiol. 2005;34(4):781–8.CrossRefPubMedGoogle Scholar
  46. 46.
    Uuskula A, Laisaar KT, Raag M, Amico KR, Sharma A, DeHovitz J. Antiretroviral therapy (ART) adherence and correlates to non-adherence among people on ART in Estonia. AIDS Care. 2012;24(12):1470–9.CrossRefPubMedGoogle Scholar
  47. 47.
    Zimet GD, Powell SS, Farley GK, Werkman S, Berkoff KA. Psychometric characteristics of the multidimensional scale of perceived social support. J Pers Assess. 1990;55(3–4):610–7.CrossRefPubMedGoogle Scholar
  48. 48.
    Canty-Mitchell J, Zimet GD. Psychometric properties of the Multidimensional Scale of Perceived Social Support in urban adolescents. Am J Community Psychol. 2000;28(3):391–400.CrossRefPubMedGoogle Scholar
  49. 49.
    Berger BE, Ferrans CE, Lashley FR. Measuring stigma in people with HIV: psychometric assessment of the HIV stigma scale. Res Nurs Health. 2001;24(6):518–29.CrossRefPubMedGoogle Scholar
  50. 50.
    Culbert GJ. Violence and the perceived risks of taking antiretroviral therapy in US jails and prisons. Int J Prison Health. 2014;10(2):94–110.CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    McKee KJ, Markova I, Power KG. Concern, perceived risk and attitudes towards HIV/AIDS in Scottish prisons. AIDS Care. 1995;7(2):159–70.CrossRefPubMedGoogle Scholar
  52. 52.
    Forste R, Clarke L, Bahr S. Staying out of trouble: intentions of young male offenders. Int J Offender Ther Comp Criminol. 2011;55(3):430–44.CrossRefPubMedGoogle Scholar
  53. 53.
    Dhami MK, Mandel DR, Loewenstein G, Ayton P. Prisoners’ positive illusions of their post-release success. Law Hum Behav. 2006;30(6):631–47.CrossRefPubMedGoogle Scholar
  54. 54.
    Preacher KJ, Rucker DD, Hayes AF. Addressing moderated mediation hypotheses: theory, methods, and prescriptions. Multivar Behav Res. 2007;42:185–227.CrossRefGoogle Scholar
  55. 55.
    Bollen KA, Stine RA. Bootstrapping goodness-of-fit measures in structural equation models. Sociol Methods Res. 1992;21(2):205–29.CrossRefGoogle Scholar
  56. 56.
    Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1–2):83–8.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Rich JD, McKenzie M, Larney S, Wong JB, Tran L, Clarke J, Noska A, Reddy M, Zaller N. Methadone continuation versus forced withdrawal on incarceration in a combined US prison and jail: a randomised, open-label trial. Lancet. 2015;386(9991):350–9.CrossRefPubMedPubMedCentralGoogle Scholar
  58. 58.
    Stöver H. HIV/AIDS prevention care, treatment and support in prision setting. A framework for and effective national response. In: United Nations Office on Drugs and Crime/World Health Organization, Geneva; 2006.Google Scholar
  59. 59.
    United Nations Office on Drugs and Crime (UNODC). Drug dependence treatment: interventions for drug users in prison. Vienna, Austria: TreatNet, 2012 Contract No.: GLO/H43.Google Scholar
  60. 60.
    (WHO) WHO. Tool to set and monitor targets for HIV prevention, diagnosis, treatment and care for key populations. Geneva, Switzerland2015. http://www.aidsdatahub.org/sites/default/files/toolandguide/document/WHO_Tool_to_set_and_monitor_targets_for_HIV_prevention_diagnosis_treatment_and_care_for_key_populations_.pdf. Accessed 2 Aug 2015
  61. 61.
    Goffman E. Stigma: notes on the management of spoiled identity. Englewood Cliffs: Prentice-Hall; 1963.Google Scholar
  62. 62.
    Festinger L. A theory of social comparison processes. Hum Relat. 1954;7:117–42.CrossRefGoogle Scholar
  63. 63.
    Comfort M. Doing time together: love and family in the shadow of the prison. Chicago: University of Chicago Press; 2009.Google Scholar
  64. 64.
    Harding DJ, Wyse JJ, Dobson C, Morenoff JD. Making ends meet after prison. J Policy Anal Manag. 2014;33(2):440–70.CrossRefGoogle Scholar
  65. 65.
    Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.CrossRefPubMedGoogle Scholar
  66. 66.
    Bojko MJ, Mazhnaya A, Makarenko I, Marcus R, Dvoriak S, Islam Z, et al. Bureaucracy & beliefs: assessing the barriers to accessing opioid substitution therapy by people who inject drugs in Ukraine. Drugs. 2015;22(3):255–62.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Izenberg JM, Bachireddy C, Wickersham JA, Soule M, Kiriazova T, Dvoriak S, et al. Within-prison drug injection among HIV-infected Ukrainian prisoners: prevalence and correlates of an extremely high-risk behaviour. Int J Drug Policy. 2014;25(5):845–52.CrossRefPubMedPubMedCentralGoogle Scholar
  68. 68.
    Bryan A, Schmiege SJ, Broaddus MR. Mediational analysis in HIV/AIDS research: estimating multivariate path analytic models in a structural equation modeling framework. AIDS Behav. 2007;11(3):365–83.CrossRefPubMedGoogle Scholar
  69. 69.
    Altice FL, Mostashari F, Friedland GH. Trust and the acceptance of and adherence to antiretroviral therapy. J Acquir Immune Defic Syndr. 2001;28(1):47–58.CrossRefPubMedGoogle Scholar
  70. 70.
    Culbert GJ, Bazazi AR, Waluyo A, Murni A, Muchransyah AP, Iriyanti M, et al. The influence of medication attitudes on utilization of antiretroviral therapy (ART) in indonesian prison. AIDS Behav. 2015:1–13.Google Scholar
  71. 71.
    Culbert GJ, Earnshaw VA, Wulanyani NM, Wegman MP, Waluyo A, Altice FL. Correlates and experiences of HIV stigma in prisoners living with HIV in Indonesia: a mixed-method analysis. J Assoc Nurses AIDS Care. 2015;26(6):743–57.CrossRefPubMedPubMedCentralGoogle Scholar
  72. 72.
    Izenberg J, Altice FL. Next steps for Ukraine—abolition of HIV registries, implementation of routine HIV testing and expansion of services. Addiction. 2010;105(3):569–70.CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Bojko MJ, Dvoriak S, Altice FL. At the crossroads: HIV prevention and treatment for people who inject drugs in Ukraine. Addiction. 2013;108(10):1697–9.CrossRefPubMedPubMedCentralGoogle Scholar
  74. 74.
    Izenberg JM, Bachireddy C, Soule M, Kiriazova T, Dvoryak S, Altice FL. High rates of police detention among recently released HIV-infected prisoners in Ukraine: implications for health outcomes. Drug Alcohol Depend. 2013;133(1):154–60.CrossRefPubMedPubMedCentralGoogle Scholar
  75. 75.
    American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders (DSM-V). 5th ed. 5Washington, DC: American Psychiatric Association; 2013.CrossRefGoogle Scholar
  76. 76.
    Gordon MS, Kinlock TW, Miller PM. Medication-assisted treatment research with criminal justice populations: challenges of implementation. Behav Sci Law. 2011;29(6):829–45.CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33–40.CrossRefPubMedGoogle Scholar
  78. 78.
    Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72(1):59–65.CrossRefPubMedGoogle Scholar
  79. 79.
    Dolan KA, Shearer J, White B, Zhou J, Kaldor J, Wodak AD. Four-year follow-up of imprisoned male heroin users and methadone treatment: mortality, re-incarceration and hepatitis C infection. Addiction. 2005;100(6):820–8.CrossRefPubMedGoogle Scholar
  80. 80.
    Springer SA, Larney S, Alam-Mehrjerdi Z, Altice FL, Metzger D, Shoptaw S. Drug treatment as HIV prevention among women and girls who inject drugs from a global perspective: progress, gaps, and future directions. J Acquir Immune Defic Syndr. 2015;69:S155–61.CrossRefPubMedPubMedCentralGoogle Scholar
  81. 81.
    Meyer JP, Cepeda J, Taxman FS, Altice FL. Sex-related disparities in criminal justice and HIV treatment outcomes: a retrospective cohort study of HIV-infected inmates. Am J Public Health. 2015;105(9):1901–10.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on buprenorphine is associated with high levels of maximal viral suppression among HIV-infected opioid dependent released prisoners. PLoS One. 2012;7(5):e38335.CrossRefPubMedPubMedCentralGoogle Scholar
  83. 83.
    Wickersham JA, Zahari MM, Azar MM, Kamarulzaman A, Altice FL. Methadone dose at the time of release from prison significantly influences retention in treatment: implications from a pilot study of HIV-infected prisoners transitioning to the community in Malaysia. Drug Alcohol Depend. 2013;132(1–2):378–82.CrossRefPubMedPubMedCentralGoogle Scholar
  84. 84.
    Wickersham JA, Marcus R, Kamarulzaman A, Zahari MM, Altice FL. Implementing methadone maintenance treatment in prisons in Malaysia. Bull World Health Organ. 2013;91(2):124–9.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Kunøe N, Lobmaier P, Vederhus JK, Hjerkinn B, Hegstad S, Gossop M, et al. Retention in naltrexone implant treatment for opioid dependence. Drug Alcohol Depend. 2010;111(1):166–9.CrossRefPubMedGoogle Scholar
  86. 86.
    Lobmaier PP, Kunøe N, Gossop M, Katevoll T, Waal H. Naltrexone implants compared to methadone: outcomes six months after prison release. Eur Addict Res. 2010;16(3):139–45.CrossRefPubMedGoogle Scholar
  87. 87.
    Binswanger IA, Stern MF, Deyo RA, Heagerty PJ, Cheadle A, Elmore JG, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356(2):157–65.CrossRefPubMedPubMedCentralGoogle Scholar
  88. 88.
    Merrall EL, Kariminia A, Binswanger IA, Hobbs MS, Farrell M, Marsden J, et al. Meta-analysis of drug-related deaths soon after release from prison. Addiction. 2010;105(9):1545–54.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. The Cochrane Library. 2011;4.Google Scholar
  90. 90.
    Wolfe D, Carrieri MP, Dasgupta N, Wodak A, Newman R, Bruce RD. Concerns about injectable naltrexone for opioid dependence. Lancet. 2011;377(9776):1468–70.CrossRefPubMedGoogle Scholar
  91. 91.
    Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemp Clin Trials. 2014;39(2):256–68.CrossRefPubMedPubMedCentralGoogle Scholar
  92. 92.
    Kinlock TW, Gordon MS, Schwartz RP, O’Grady KE. A study of methadone maintenance for male prisoners: 3-month postrelease outcomes. Crim Justice Behav. 2008;35(1):34–47.CrossRefPubMedPubMedCentralGoogle Scholar
  93. 93.
    Johnson BT, Eagly AH. Effects of involvement on persuasion: a Meta-analysis. Psychol Bull. 1999;106(2):290–314.CrossRefGoogle Scholar
  94. 94.
    Stangl AL, Lloyd JK, Brady LM, Holland CE, Baral S. A systematic review of interventions to reduce HIV-related stigma and discrimination from 2002 to 2013: how far have we come? J Int AIDS Soc. 2013;16(3):1–14.Google Scholar
  95. 95.
    Livingston JD, Milne T, Fang ML, Amari E. The effectiveness of interventions for reducing stigma related to substance use disorders: a systematic review. Addiction. 2012;107(1):39–50.CrossRefPubMedPubMedCentralGoogle Scholar
  96. 96.
    Polonsky M, Azbel L, Wickersham JA, Marcus R, Doltu S, Grishaev E, et al. Accessing methadone within Moldovan prisons: prejudice and myths amplified by peers. Int J Drug Policy. 2016;29:91–5.CrossRefPubMedGoogle Scholar
  97. 97.
    Epley N, Mak D, Idson LC. Bonus of rebate?: the impact of income framing on spending and saving. J Behav Decis Mak. 2006;19(3):213.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2016

Authors and Affiliations

  • Maxim Polonsky
    • 1
  • Julia Rozanova
    • 1
  • Lyuba Azbel
    • 2
  • Chethan Bachireddy
    • 3
  • Jacob Izenberg
    • 4
  • Tetiana Kiriazova
    • 5
  • Sergii Dvoryak
    • 5
  • Frederick L. Altice
    • 1
    • 6
    • 7
  1. 1.Section of Infectious DiseasesYale University School of MedicineNew HavenUSA
  2. 2.London School of Hygiene and Tropical MedicineLondonUK
  3. 3.Department of Medicine, Brigham and Women’s Hospital, Harvard Medical SchoolBostonUSA
  4. 4.Department of PsychiatryUniversity of California San Francisco School of MedicineSan FranciscoUSA
  5. 5.Ukrainian Institute on Public Health PolicyKievUkraine
  6. 6.Department of Epidemiology of Microbial DiseasesYale School of Public HealthNew HavenUSA
  7. 7.University of Malaya, Centre of Excellence on Research in AIDS (CERiA)Kuala LumpurMalaysia

Personalised recommendations